140 related articles for article (PubMed ID: 36608961)
1. Autologous Anti-CD19 CAR T Cells as Therapy for Systemic Lupus Erythematosus.
Radic M; Randolph B
Transplant Cell Ther; 2023 Jan; 29(1):3-4. PubMed ID: 36608961
[No Abstract] [Full Text] [Related]
2. Treatment of SLE with anti-CD19 CAR-T cells.
Carney EF
Nat Rev Nephrol; 2022 Dec; 18(12):743. PubMed ID: 36323874
[No Abstract] [Full Text] [Related]
3. Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus.
Jin X; Xu Q; Pu C; Zhu K; Lu C; Jiang Y; Xiao L; Han Y; Lu L
Cell Mol Immunol; 2021 Aug; 18(8):1896-1903. PubMed ID: 32472023
[TBL] [Abstract][Full Text] [Related]
4. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus.
Kansal R; Richardson N; Neeli I; Khawaja S; Chamberlain D; Ghani M; Ghani QU; Balazs L; Beranova-Giorgianni S; Giorgianni F; Kochenderfer JN; Marion T; Albritton LM; Radic M
Sci Transl Med; 2019 Mar; 11(482):. PubMed ID: 30842314
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic intersections: Expanding benefits of CD19 CAR T cells from cancer to autoimmunity.
Sosnoski HM; Posey AD
Cell Stem Cell; 2024 Apr; 31(4):437-438. PubMed ID: 38579681
[TBL] [Abstract][Full Text] [Related]
6. CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus.
Mougiakakos D; Krönke G; Völkl S; Kretschmann S; Aigner M; Kharboutli S; Böltz S; Manger B; Mackensen A; Schett G
N Engl J Med; 2021 Aug; 385(6):567-569. PubMed ID: 34347960
[No Abstract] [Full Text] [Related]
7. [Systemic lupus erythematosus: A new indication for CAR-T cell therapies?].
Desvaux E; Moingeon P; Bril A; Trebeden-Negre H
Med Sci (Paris); 2022 Apr; 38(4):337-339. PubMed ID: 35485890
[No Abstract] [Full Text] [Related]
8. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus.
Mackensen A; Müller F; Mougiakakos D; Böltz S; Wilhelm A; Aigner M; Völkl S; Simon D; Kleyer A; Munoz L; Kretschmann S; Kharboutli S; Gary R; Reimann H; Rösler W; Uderhardt S; Bang H; Herrmann M; Ekici AB; Buettner C; Habenicht KM; Winkler TH; Krönke G; Schett G
Nat Med; 2022 Oct; 28(10):2124-2132. PubMed ID: 36109639
[TBL] [Abstract][Full Text] [Related]
9. CAR-T cell therapy in systemic lupus erythematosus and beyond: a brave new world?
van Leuven SI; Duivenvoorden R
Rheumatology (Oxford); 2024 May; 63(5):1192-1194. PubMed ID: 38377390
[No Abstract] [Full Text] [Related]
10. Successful Generation of CD19 Chimeric Antigen Receptor T Cells from Patients with Advanced Systemic Lupus Erythematosus.
Kretschmann S; Völkl S; Reimann H; Krönke G; Schett G; Achenbach S; Lutzny-Geier G; Müller F; Mougiakakos D; Dingfelder J; Flamann C; Hanssens L; Gary R; Mackensen A; Aigner M
Transplant Cell Ther; 2023 Jan; 29(1):27-33. PubMed ID: 36241147
[TBL] [Abstract][Full Text] [Related]
11. CAR-T cell therapy: new hope for systemic lupus erythematosus patients.
Jin X; Han Y; Wang JQ; Lu L
Cell Mol Immunol; 2021 Dec; 18(12):2581-2582. PubMed ID: 34737415
[No Abstract] [Full Text] [Related]
12. Prospects for CAR T cell immunotherapy in autoimmune diseases: clues from Lupus.
Radic M; Neeli I; Marion T
Expert Opin Biol Ther; 2022 Apr; 22(4):499-507. PubMed ID: 35089116
[TBL] [Abstract][Full Text] [Related]
13. More on CD19-CAR T Cells in Systemic Lupus Erythematosus.
Konig MF; Paul S
N Engl J Med; 2021 Nov; 385(19):e67. PubMed ID: 34731550
[No Abstract] [Full Text] [Related]
14. More on CD19-CAR T Cells in Systemic Lupus Erythematosus. Reply.
Mougiakakos D; Krönke G; Schett G
N Engl J Med; 2021 Nov; 385(19):e67. PubMed ID: 34731551
[No Abstract] [Full Text] [Related]
15. Adoptive Treg Cell Therapy in a Patient With Systemic Lupus Erythematosus.
Dall'Era M; Pauli ML; Remedios K; Taravati K; Sandova PM; Putnam AL; Lares A; Haemel A; Tang Q; Hellerstein M; Fitch M; McNamara J; Welch B; Bluestone JA; Wofsy D; Rosenblum MD;
Arthritis Rheumatol; 2019 Mar; 71(3):431-440. PubMed ID: 30277008
[TBL] [Abstract][Full Text] [Related]
16. New insights in systemic lupus erythematosus: From regulatory T cells to CAR-T-cell strategies.
Doglio M; Alexander T; Del Papa N; Snowden JA; Greco R;
J Allergy Clin Immunol; 2022 Dec; 150(6):1289-1301. PubMed ID: 36137815
[TBL] [Abstract][Full Text] [Related]
17. Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL.
Wang X; Popplewell LL; Wagner JR; Naranjo A; Blanchard MS; Mott MR; Norris AP; Wong CW; Urak RZ; Chang WC; Khaled SK; Siddiqi T; Budde LE; Xu J; Chang B; Gidwaney N; Thomas SH; Cooper LJ; Riddell SR; Brown CE; Jensen MC; Forman SJ
Blood; 2016 Jun; 127(24):2980-90. PubMed ID: 27118452
[TBL] [Abstract][Full Text] [Related]
18. Modeling anti-CD19 CAR T cell therapy in humanized mice with human immunity and autologous leukemia.
Jin CH; Xia J; Rafiq S; Huang X; Hu Z; Zhou X; Brentjens RJ; Yang YG
EBioMedicine; 2019 Jan; 39():173-181. PubMed ID: 30579863
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.
Kochenderfer JN; Dudley ME; Kassim SH; Somerville RP; Carpenter RO; Stetler-Stevenson M; Yang JC; Phan GQ; Hughes MS; Sherry RM; Raffeld M; Feldman S; Lu L; Li YF; Ngo LT; Goy A; Feldman T; Spaner DE; Wang ML; Chen CC; Kranick SM; Nath A; Nathan DA; Morton KE; Toomey MA; Rosenberg SA
J Clin Oncol; 2015 Feb; 33(6):540-9. PubMed ID: 25154820
[TBL] [Abstract][Full Text] [Related]
20. CD19 CAR-T Cells With Membrane-Bound IL-15 for B-Cell Acute Lymphoblastic Leukemia After Failure of CD19 and CD22 CAR-T Cells: Case Report.
Sun Y; Su Y; Wang Y; Liu N; Li Y; Chen J; Qiao Z; Niu J; Hu J; Zhang B; Ning H; Hu L
Front Immunol; 2021; 12():728962. PubMed ID: 34691036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
